Literature DB >> 436304

Plasma levels of norethindrone after single oral dose administration of norethindrone and lynestrenol.

V Odlind, E Weiner, A Victor, E D Johansson.   

Abstract

Single oral doses of 0.3 mg, 0.5 mg and 5 mg Norethindrone (NET) and 0.5 mg and 5 mg Lynestrenol (lyn) were given to five women. Lynestrenol is probably metabolized through NET and exerts its main biological activity as NET. Plasma concentrations of NET were determined by a radioimmunoassay at different intervals after administration of the tablets. Peak concentrations of NET were found within two hours after intake of each table. The plasma half life of Net after NET and lyn administration for the period 8-24 h was 8-11 h. No significant difference was found between the half life of NET and the NET tablets and after the lyn tablets. When 5 mg NET was given the plasma half life of NET for the period 24-72 h was around 10 h and this was significantly shorter than the half-life of NET after 5 mg lyn, which was 16 1/2 h. The systemic availability of the drugs was estimated by calculating and comparing the areas under the plasma concentration versus time curve (AUC). 0-24 H. The AUC 0.24 after 0.3 MG NET was almost identical to the AUC 0.24 after 0.5 mg lyn. The AUC 0-24 after 0.5 mg NET was significantly larger than after 0.5 lyn. No difference was found between the AUC 0-24 after 5 mg lyn and 5 mg NET. This study supports the concept of a conversion from lyn to NET. It also shows that there were only minor pharmacokinetic differences between the drugs when all samples were measured as NET.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 436304     DOI: 10.1111/j.1365-2265.1979.tb03030.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  4 in total

Review 1.  Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception.

Authors:  Frank Z Stanczyk
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

Review 2.  Clinical pharmacokinetics of oral contraceptive steroids.

Authors:  M L Orme; D J Back; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1983 Mar-Apr       Impact factor: 6.447

3.  Progestin treatment depresses estrogen receptor but not cathepsin D levels in needle aspirates of benign breast disease.

Authors:  T Maudelonde; P Lavaud; G Salazar; F Laffargue; H Rochefort
Journal:  Breast Cancer Res Treat       Date:  1991-10       Impact factor: 4.872

4.  Effect of protease inhibitors on steady-state pharmacokinetics of oral norethindrone contraception in HIV-infected women.

Authors:  Jessica Atrio; Frank Z Stanczyk; Michael Neely; Ganesh Cherala; Andrea Kovacs; Daniel R Mishell
Journal:  J Acquir Immune Defic Syndr       Date:  2014-01-01       Impact factor: 3.731

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.